AstraZeneca plans to invest $50 billion in the U.S. by the end of the decade, driven by pressure from the Trump administration for pharmaceutical companies to relocate operations domestically. This investment aims to achieve $80 billion in annual sales by 2030, with half from the U.S. The investment includes a new manufacturing facility in Virginia focused on chronic disease treatments. The move has raised questions about AstraZeneca's long-term commitment to the UK, where it is headquartered. Political pressure from the White House has emphasized national security concerns regarding foreign-produced medicines.
AstraZeneca has announced plans to invest $50 billion in the United States by the end of the decade, responding to mounting pressure from the Trump administration for global pharmaceutical firms to shift manufacturing and research operations to American soil.
The investment will help AstraZeneca reach its target of $80 billion in annual sales by 2030, with half of that revenue expected to come from the US.
A key component of the investment includes the construction of a new manufacturing facility in Virginia dedicated to the company's growing portfolio of chronic disease treatments.
US Commerce Secretary Howard Lutnick welcomed AstraZeneca's commitment, stating that the investment aligns with the administration's broader goal of ending American reliance on foreign pharmaceutical supply chains.
Collection
[
|
...
]